WOODMERE, NY / ACCESSWIRE / September 7, 2021 / Geoff Girnun is a research scientist who has contributed a great deal to his field. He found his beginnings in Johannesburg, South Africa. When he was five years old, he moved with his family to Israel. After this, they moved to the United States, where they lived in the states of Iowa and Florida. In Florida, Girnun attended Lake Brantley High School. In 1989, he continued his studies at the University of Iowa. He then went to the University of Iowa Roy J. and Lucille A. Carver College of Medicine between 1994 and 1999, ultimately earning an MS and a PhD in biochemistry and molecular biology in 1999. After this, Girnun was a postdoc at Harvard Medical School, as well as the Dana-Farber Cancer Institute. In 2007, he began his work at the University of Maryland School of Medicine.
Geoff Girnun has been an integral part of many scientific studies. He was the lead researcher in a study that demonstrated that metformin can be a protective agent against liver cancer. Metformin is a very commonly used drug among diabetics. This study was the first to evaluate the effect of this drug on liver cancer. Basically, they would chemically induce liver tumors in mice. The mice that were taking metformin had significantly lower amounts of tumor activity when compared to the ones in the control group. Girnun and his fellow researchers also showed that inhibited lipid synthesis within the liver might be part of the mechanism that metformin uses in order to help prevent liver cancer.
This is not the only study that Geoff Girnun has done. He has done multiple molecular biology studies on cancer cells. In one of these studies, it was shown that HectH9 is a novel regulator of Hexokinase 2, or HK2, metabolism. This is integral in glycolysis activation and resilience in apoptosis, in addition to cancer metabolism. Additionally, targeting this regulator appears to be an effective strategy when it comes to long-term tumor remission. Geoff Girnun also studied the inhibition of phosphoenolpyruvate carboxykinase and its potentially medically beneficial impact when it comes to colorectal cancer. There have also been numerous other studies of which Girnun has been a part, and these have all played a role in the field.
When he is not working, Geoff Girnun enjoys spending time with his family, which includes a wife, two sons, and three daughters. He also enjoys hiking, canoeing, jogging, and educating people on connections between science and religion, particularly ones that reference the Torah. He has spoken many times at synagogues and other religious programs. He likes to impart all of the knowledge that he has gained in the field of science and medicine over the years and help other people learn and grow.
CONTACT:
Caroline Hunter
Web Presence, LLC
+1 786-551-9491
SOURCE: Geoff Girnun